ALK and inflammatory myofibroblastic tumor: A clinical trial (Briga-PED, NCT04925609) is in progress to study the efficacy of brigatinib in pediatric and young adult (≤ 25-year-old) patients with ALK+ anaplastic large cell lymphoma, IMT, and other solid tumors, with an estimated study completion date by December 2030 [106].